Subcutaneous Daratumumab Potential Game Changer for Multiple Myeloma

No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research

Related Links:

Authors: Shimizu Y, Inoue H, Hishinuma S, Shoji M Abstract OBJECTIVE: Molecular targeting pharmacotherapy (MTP) with proteasome inhibitors and immunomodulatory drugs has led to a remarkable improvement in the effectiveness of multiple myeloma (MM) therapy. However, the effect of MTP on the occurrence of infections in patients with MM remains unclear. We aimed to identify the incidence of and risk factors for bloodstream infection (BSI) in patients with MM undergoing MTP. MATERIALS AND METHODS: We conducted a retrospective cohort study. We reviewed the medical records of 108 inpatients with MM at the National De...
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Authors: Hou J, Wei R, Qian J, Wang R, Fan Z, Gu C, Yang Y Abstract Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells in the bone marrow (BM). The interaction between the BM microenvironment and MM plasma cells can influence cell proliferation, drug resistance and prognosis of the disease. The BM microenvironment (BMME) consists of a cellular and non‑cellular compartment. The cellular compartment includes stromal cells, endothelial cells, osteoclasts and osteoblasts, and the non‑cellular compartment includes the extracellular matrix (ECM) and the liquid milieu, which contains...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Publication date: November 2019Source: Biomedicine &Pharmacotherapy, Volume 119Author(s): Zhouxiang Jin, Shujuan Zhou, Haige Ye, Songfu Jiang, Kang Yu, Yongyong MaAbstractOur previous research had firstly shown that MM cells overexpressed IQGAP1 gene and activated Ras/Raf/MEK/ERK pathway. But the mechanism of IQGAP1 overexpression and IQGAP1 gene transcription regulation remains uncertain. The mechanism of IQGAP1 overexpression and transcriptional regulation of IQGAP1 gene in myeloma cells was explored in the study. Through bioinformatics analysis and prediction we predicted and screened transcription factor Sp1 as a p...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conditions:   Advanced Solid Tumors;   B Cell Lymphoma;   Multiple Myeloma Intervention:   Drug: DeltaRex-G Sponsor:   Aveni Foundation Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Malignant Solid Neoplasm;   Caregiver;   Metastatic Malignant Solid Neoplasm;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma Intervention:   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Solid Tumors;   B Cell Lymphoma;   Multiple Myeloma Intervention:   Drug: DeltaRex-G Sponsor:   Aveni Foundation Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Malignant Solid Neoplasm;   Caregiver;   Metastatic Malignant Solid Neoplasm;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma Intervention:   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Bone Marrow Transplantation, Published online: 16 September 2019; doi:10.1038/s41409-019-0671-5Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Cancer & Oncology | Myeloma